Wockhardt to Hold 27th AGM on August 10, 2026; Seeks Approval for ₹3,000 Crore Capital Raise

4 min read     Updated on 18 Jul 2026, 09:46 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Wockhardt Limited has scheduled its 27th AGM on August 10, 2026 via VC/OAVM, seeking shareholder approval for a ₹3,000 Crore capital raise through QIP or other modes, revision of Executive Chairman Dr. Habil Khorakiwala's remuneration up to ₹15 Crore per annum, material related party transactions with subsidiaries Wockhardt Bio AG, CP Pharmaceuticals Limited and Wockhardt UK Limited, appointment of Ms. Zahabiya Khorakiwala as Executive Co-chairperson of Wockhardt Bio AG at USD 250,000 per annum, and redeployment of approximately ₹162.33 Crore in unutilised QIP proceeds from the November 2024 placement towards R&D and capital expenditure.

powered bylight_fuzz_icon
45849935

*this image is generated using AI for illustrative purposes only.

Wockhardt Limited has announced the convening of its 27th Annual General Meeting (AGM) on Monday, August 10, 2026, at 3:30 p.m. (IST), to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The notice, issued pursuant to Regulations 29, 30 and 34(1) of the SEBI Listing Regulations, was filed by Company Secretary Rashmi Mamtura on July 17, 2026. The AGM shall be deemed to be held at the Registered Office of the Company at D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar – 431 006.

Key AGM Agenda Items

The meeting will transact both ordinary and special business. The ordinary business includes adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and the re-appointment of Ms. Zahabiya Khorakiwala (DIN: 00102689), who retires by rotation and offers herself for re-appointment.

The following table summarises the key resolutions proposed at the 27th AGM:

Resolution: Nature Key Details
Cost Auditor Remuneration Ratification: Ordinary ₹3,85,000 plus taxes payable to Kirit Mehta & Co. LLP for FY 2026-27
Executive Chairman Remuneration Revision: Special Up to ₹10 Crore p.a. (March 1, 2027 – February 29, 2028); ceiling of ₹15 Crore p.a. thereafter
RPT – Wockhardt Bio AG: Ordinary Aggregate value up to ₹1,000 Crore for sale of goods, services and IP transfer
RPT – CP Pharmaceuticals Limited: Ordinary Aggregate value up to ₹550 Crore for purchase/sale of goods and services
RPT – Wockhardt UK Limited: Ordinary Aggregate value up to ₹550 Crore for sale of goods and services
Capital Raising (QIP/Other Modes): Special Amount not exceeding ₹3,000 Crore via equity shares or eligible securities
Ms. Zahabiya Khorakiwala Appointment: Ordinary Executive Co-chairperson of Wockhardt Bio AG at USD 250,000 per annum w.e.f. May 4, 2026
QIP Proceeds Redeployment: Special Redeployment of unutilised proceeds of approximately ₹162.33 Crore from November 11, 2024 QIP

Executive Remuneration Revision

The Board of Directors and the Nomination and Remuneration Committee, at their respective meetings held on May 4, 2026, proposed a revision in remuneration payable to Dr. Habil Khorakiwala, Executive Chairman, for the remaining three years of his tenure from March 1, 2027 to February 28, 2030. The revised remuneration will be ₹10 Crore per annum for the period commencing from March 1, 2027 till February 29, 2028, which may be further revised from time to time till February 28, 2030, subject to an overall ceiling of ₹15 Crore per annum. Dr. Habil Khorakiwala was originally appointed as Executive Chairman for a term of five years at the Twenty-Fifth AGM held on June 28, 2024.

Capital Raising and QIP Proceeds Redeployment

The company seeks enabling approval to issue securities for a value not exceeding ₹3,000 Crore (Rupees Three Thousand Crore Only) or its equivalent in any foreign currency, through one or more public and/or private offerings including a Qualified Institutions Placement (QIP). The proceeds may be utilised for business purposes including capital expenditure, research and development, repayment/prepayment of long-term and short-term debt, and general corporate purposes.

Separately, shareholders will vote on the redeployment of unutilised QIP proceeds from the November 11, 2024 placement. The following table details the original use of proceeds and the current utilisation status as of March 31, 2026:

Item Head: Amount Proposed (₹ Crore) Amount Utilised as of March 31, 2026 (₹ Crore) Balance (₹ Crore)
Repayment/pre-payment of borrowings: 500.00 500 0
Capital expenditure, R&D and incidental expenses: 250.00 87.67 162.33
General corporate purposes: 227.79 227.79 0
Total: 977.79 815.46 162.33

The company proposes to redeploy the unutilised balance of approximately ₹162.33 Crore towards funding capital expenditure and investment in targeted R&D activities encompassing Biosimilar, New Chemical Entities (NCE) and other products. The Board of Directors has also extended the timeline for utilisation of such funds from financial year 2026 up to financial year 2028.

Material Related Party Transactions

The company seeks member approval for material related party transactions with three subsidiaries. Transactions with Wockhardt Bio AG — a subsidiary in which Wockhardt holds 85.85% — include sale of goods, recovery of management and technical fees, and transfer of Intellectual Property Rights, with an aggregate value up to ₹1,000 Crore. During FY 2025-26, transactions with Wockhardt Bio AG aggregated to ₹584.33 Crore. Proposed transactions between Wockhardt Bio AG and CP Pharmaceuticals Limited (a step-down subsidiary) and between Wockhardt Bio AG and Wockhardt UK Limited are each capped at ₹550 Crore.

Ms. Zahabiya Khorakiwala's Appointment at Wockhardt Bio AG

The Board approved the appointment of Ms. Zahabiya Khorakiwala as Executive Co-chairperson of Wockhardt Bio AG with effect from May 4, 2026, at a remuneration of USD 250,000 per annum, together with such benefits and reimbursements as may be approved in accordance with applicable policies. Her responsibilities will include market access strategy, stakeholder engagement, and partnership development for the company's Global NCE portfolio with a focus on the United States and allied markets.

E-Voting and AGM Schedule

Key dates for the AGM process are as follows:

Parameter: Details
AGM Date: Monday, August 10, 2026 at 3:30 p.m. (IST)
Record/Cut-off Date: Monday, August 3, 2026
E-Voting Start: Friday, August 7, 2026 at 9:00 a.m. (IST)
E-Voting End: Sunday, August 9, 2026 at 5:00 p.m. (IST)
Speaker Registration Window: July 31, 2026 (9:00 a.m.) to August 6, 2026 (5:00 p.m.)

E-voting services are being provided by NSDL. Mr. Virendra Bhatt, Practicing Company Secretary (ACS No. 1157, CP No. 124/Peer Review Certificate No. 6489/2025), has been appointed as Scrutinizer for the remote e-voting process.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE049B01025/1aaad7bf-1ec6-4ac2-97dc-2c8a6234d2b3.pdf

Historical Stock Returns for Wockhardt

1 Day5 Days1 Month6 Months1 Year5 Years
+1.30%+3.79%-0.96%+33.14%+4.38%+260.03%

What specific strategic initiatives or acquisitions is Wockhardt targeting with the proposed ₹3,000 Crore capital raising?

How will the significant increase in the Executive Chairman's remuneration impact shareholder sentiment and governance perceptions?

What are the expected revenue contributions from the Global NCE portfolio that Ms. Zahabiya Khorakiwala will focus on?

Wockhardt files Business Responsibility and Sustainability Report for FY26

1 min read     Updated on 17 Jul 2026, 10:01 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Wockhardt Limited filed its Business Responsibility and Sustainability Report for FY26, reporting a 19% drop in Scope 2 emissions and a 5.9% reduction in non-renewable energy use. The company, which exports 56.86% of its turnover, received reasonable assurance from SGS India for its BRSR Core data. The report also details a GST penalty of ₹28.07 lakh and improvements in waste management.

powered bylight_fuzz_icon
45851495

*this image is generated using AI for illustrative purposes only.

Wockhardt Limited has submitted its Business Responsibility and Sustainability Report for the financial year ended March 31, 2026, to the stock exchanges. The filing, made pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company's environmental, social, and governance (ESG) performance. SGS India Private Limited provided reasonable assurance for the BRSR Core parameters in accordance with the ISAE 3000 (revised) standard.

The report highlights a reduction in non-renewable energy consumption by approximately 5.9%, decreasing from 340,999.21 GJ to 320,753.11 GJ during the year. Additionally, Scope 2 emissions fell by roughly 19% to 49,637.06 tCO₂e from 61,310.66 tCO₂e in the previous year. The company also reported improvements in energy intensity, which enhanced by 19% on a PPP-adjusted basis, and a significant reduction in SOx emissions by 48%.

Operational and Employee Metrics

Wockhardt's operations span 10 locations nationally and 21 internationally, with exports contributing 56.86% to the total turnover. The company reported a total workforce of 4,084, comprising 3,603 employees and 481 workers. The Board of Directors includes 9 members, with female representation at 22.22%, while Key Management Personnel have 25% female representation.

The company recorded a penalty of ₹28,07,984 from the Superintendent, Central GST Range-11, regarding a demand raised for FY 2019-20. An appeal has been filed with the GST Appellate Authority against this order.

Environmental Performance

Wockhardt maintained 100% recycling of e-waste and battery waste through authorized recyclers. Non-hazardous waste generation decreased by approximately 66.8% to 1,837.31 metric tonnes. The company implemented Zero Liquid Discharge (ZLD) at its Shendra factory and R&D units in Chhatrapati Sambhajinagar and Daman, treating wastewater for reuse in gardening.

Parameter FY 2025-26 FY 2024-25
Total energy consumed (GJ) 504,887.29 494,858.56
Total Scope 1 emissions (tCO₂e) 10,430.89 8,738.84
Total Scope 2 emissions (tCO₂e) 49,637.06 61,310.66
Total water consumption (kL) 406,722 404,733.8
Total waste generated (metric tonnes) 1,931.45 5,580.86

Governance and Disclosures

The Corporate Social Responsibility Committee of the Board oversees matters related to Environmental, Social, and Governance. The report confirms that the company has policies covering all nine principles of the National Guidelines on Responsible Business Conduct (NGRBC). Wockhardt also disclosed that it has no operations in ecologically sensitive areas and is compliant with applicable environmental laws.

Historical Stock Returns for Wockhardt

1 Day5 Days1 Month6 Months1 Year5 Years
+1.30%+3.79%-0.96%+33.14%+4.38%+260.03%

How will Wockhardt sustain the 19% reduction in Scope 2 emissions as production scales up?

What are the capital expenditure plans to extend Zero Liquid Discharge technology to remaining manufacturing sites?

Will the company set specific targets to increase female representation beyond the current 22.22% on the Board?

More News on Wockhardt

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:+4.38%